WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
INCY
INCYTE CORP
$11.84BN/A0.00%N/AN/AN/AN/A
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$1.66BN/A0.00%N/AN/AN/AN/A
VYGR
VOYAGER THERAPEUTICS INC
$420.29MN/A0.00%N/AN/AN/AN/A
AMLX
AMYLYX PHARMACEUTICALS INC
$135.56MN/A0.00%N/AN/AN/AN/A
UTHR
UNITED THERAPEUTICS CORP
$11.07BN/A0.00%N/AN/AN/AN/A
CORT
CORCEPT THERAPEUTICS INC
$2.38BN/A0.00%N/AN/AN/AN/A
EXEL
EXELIXIS INC
$6.93BN/A0.00%N/AN/AN/AN/A
PBYI
PUMA BIOTECHNOLOGY INC
$249.23MN/A0.00%N/AN/AN/AN/A
MDXG
MIMEDX GROUP INC
$930.25MN/A0.00%N/AN/AN/AN/A
HALO
HALOZYME THERAPEUTICS INC
$4.82BN/A0.00%N/AN/AN/AN/A
RPRX
ROYALTY PHARMA PLC
$16.50B1.45%23.60%$0.2000$0.4028%0
TGTX
TG THERAPEUTICS INC
$2.13BN/A0.00%N/AN/AN/AN/A
ROIV
ROIVANT SCIENCES LTD
$8.41BN/A0.00%N/AN/AN/AN/A
BMRN
BIOMARIN PHARMACEUTICAL INC
$17.07BN/A0.00%N/AN/AN/AN/A
GMAB
GENMAB A
$18.85BN/A0.00%N/AN/AN/AN/A
MEIP
MEI PHARMA INC
$22.05M52.87%58.90%$1.7500$1.75100%0
BNTX
BIONTECH SE
$20.54BN/A0.00%$2.1110N/AN/A0
VNDA
VANDA PHARMACEUTICALS INC
$301.50MN/A0.00%N/AN/AN/AN/A
DBVT
DBV TECHNOLOGIES SA
$131.15MN/A0.00%N/AN/AN/AN/A
PLX
PROTALIX BIOTHERAPEUTICS INC
$84.01MN/A0.00%N/AN/AN/AN/A
SPRO
SPERO THERAPEUTICS INC
$80.80MN/A0.00%N/AN/AN/AN/A
BNOX
BIONOMICS LIMITED
$11.08MN/A0.00%N/AN/AN/AN/A
AVRO
AVROBIO INC
$54.73MN/A0.00%N/AN/AN/AN/A
CPRX
CATALYST PHARMACEUTICALS INC
$1.89BN/A0.00%N/AN/AN/AN/A
KNSA
KINIKSA PHARMACEUTICALS LTD
$1.20BN/A0.00%N/AN/AN/AN/A
CRSP
CRISPR THERAPEUTICS AG
$4.46BN/A0.00%N/AN/AN/AN/A
SEER
SEER INC
$109.47MN/A0.00%N/AN/AN/AN/A
TFFP
TFF PHARMACEUTICALS INC
$8.16MN/A0.00%N/AN/AN/AN/A
OCUP
OCUPHIRE PHARMA INC
$43.18MN/A0.00%N/AN/AN/AN/A
IGMS
IGM BIOSCIENCES INC
$477.93MN/A0.00%N/AN/AN/AN/A
KRYS
KRYSTAL BIOTECH INC
$4.80BN/A0.00%N/AN/AN/AN/A
AXSM
AXSOME THERAPEUTICS INC
$3.30BN/A0.00%N/AN/AN/AN/A
MIRM
MIRUM PHARMACEUTICALS INC
$1.12BN/A0.00%N/AN/AN/AN/A
NVO
NOVO NORDISK A S
$561.63B1.10%38.10%$0.9299$1.3720%8
FULC
FULCRUM THERAPEUTICS INC
$442.84MN/A0.00%N/AN/AN/AN/A
REGN
REGENERON PHARMACEUTICALS INC
$98.92BN/A0.00%N/AN/AN/AN/A
IMMP
IMMUTEP LTD
$268.68MN/A0.00%N/AN/AN/AN/A
VTGN
VISTAGEN THERAPEUTICS INC
$126.21MN/A0.00%N/AN/AN/AN/A
TECH
BIO-TECHNE CORP
$9.86B0.51%22.70%$0.0800$0.328%1
IDYA
IDEAYA BIOSCIENCES INC
$3.00BN/A0.00%N/AN/AN/AN/A
AGIO
AGIOS PHARMACEUTICALS INC
$1.63BN/A0.00%N/AN/AN/AN/A
RNA
AVIDITY BIOSCIENCES INC
$1.88BN/A0.00%N/AN/AN/AN/A
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
$60.01MN/A0.00%N/AN/AN/AN/A
PRTA
PROTHENA CORP PUBLIC LTD CO
$1.13BN/A0.00%N/AN/AN/AN/A
VYNE
VYNE THERAPEUTICS INC
$33.84MN/A0.00%N/AN/AN/AN/A
JAZZ
JAZZ PHARMACEUTICALS PLC
$6.68BN/A0.00%N/AN/AN/AN/A
INM
INMED PHARMACEUTICALS INC
$1.82MN/A0.00%N/AN/AN/AN/A
GNFT
GENFIT SA
$180.90MN/A0.00%N/AN/AN/AN/A
ORMP
ORAMED PHARMACEUTICALS INC
$94.41MN/A0.00%N/AN/AN/AN/A
ADAG
ADAGENE INC
$111.62MN/A0.00%N/AN/AN/AN/A
LPCN
LIPOCINE INC
$28.28MN/A0.00%N/AN/AN/AN/A
ALGS
ALIGOS THERAPEUTICS INC
$59.55MN/A0.00%N/AN/AN/AN/A
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
$743.94MN/A0.00%N/AN/AN/AN/A
KZR
KEZAR LIFE SCIENCES INC
$59.48MN/A0.00%N/AN/AN/AN/A
MDWD
MEDIWOUND LTD
$160.83MN/A0.00%N/AN/AN/AN/A
ZLAB
ZAI LAB LTD
$1.36BN/A0.00%N/AN/AN/AN/A
XCUR
EXICURE INC
$5.17MN/A0.00%N/AN/AN/AN/A
QURE
UNIQURE NV
$223.40MN/A0.00%N/AN/AN/AN/A
ANIX
ANIXA BIOSCIENCES INC
$97.29MN/A0.00%N/AN/AN/AN/A
PTGX
PROTAGONIST THERAPEUTICS INC
$1.49BN/A0.00%N/AN/AN/AN/A
MORF
MORPHIC HOLDING INC
$1.39BN/A0.00%N/AN/AN/AN/A
GLPG
GALAPAGOS NV
$1.93BN/A0.00%N/AN/AN/AN/A
LEGN
LEGEND BIOTECH CORP
$8.88BN/A0.00%N/AN/AN/AN/A
VRTX
VERTEX PHARMACEUTICALS INC
$101.54BN/A0.00%N/AN/AN/AN/A
SAGE
SAGE THERAPEUTICS INC
$755.54MN/A0.00%N/AN/AN/AN/A
LIFE
ATYR PHARMA INC
$107.72MN/A0.00%N/AN/AN/AN/A
GBIO
GENERATION BIO CO
$198.10MN/A0.00%N/AN/AN/AN/A
FATE
FATE THERAPEUTICS INC
$522.98MN/A0.00%N/AN/AN/AN/A
BOLT
BOLT BIOTHERAPEUTICS INC
$42.32MN/A0.00%N/AN/AN/AN/A
SLGL
SOL-GEL TECHNOLOGIES LTD
$23.87MN/A0.00%N/AN/AN/AN/A
ACIU
AC IMMUNE SA
$240.06MN/A0.00%N/AN/AN/AN/A
NRBO
NEUROBO PHARMACEUTICALS INC
$16.97MN/A0.00%N/AN/AN/AN/A
XBIO
XENETIC BIOSCIENCES INC
$5.95MN/A0.00%N/AN/AN/AN/A
ABIO
ARCA BIOPHARMA INC
$46.55MN/A0.00%N/AN/AN/AN/A
ARGX
ARGENX SE
$21.68BN/A0.00%N/AN/AN/AN/A
SNSE
SENSEI BIOTHERAPEUTICS INC
$25.07MN/A0.00%N/AN/AN/AN/A
FUSN
FUSION PHARMACEUTICALS INC
$1.80BN/A0.00%N/AN/AN/AN/A
MRUS
MERUS NV
$2.38BN/A0.00%N/AN/AN/AN/A
BCYC
BICYCLE THERAPEUTICS PLC
$929.23MN/A0.00%N/AN/AN/AN/A
CLNN
CLENE INC
$43.67MN/A0.00%N/AN/AN/AN/A
MRKR
MARKER THERAPEUTICS INC
$38.37MN/A0.00%N/AN/AN/AN/A
CDTX
CIDARA THERAPEUTICS INC
$65.29MN/A0.00%N/AN/AN/AN/A
ZVRA
ZEVRA THERAPEUTICS INC
$201.50MN/A0.00%N/AN/AN/AN/A
JANX
JANUX THERAPEUTICS INC
$2.48BN/A0.00%N/AN/AN/AN/A
TRAW
TRAWS PHARMA INC
$14.37MN/A0.00%N/AN/AN/AN/A
EDIT
EDITAS MEDICINE INC
$458.98MN/A0.00%N/AN/AN/AN/A
VERV
VERVE THERAPEUTICS INC
$563.59MN/A0.00%N/AN/AN/AN/A
RYTM
RHYTHM PHARMACEUTICALS INC
$2.31BN/A0.00%N/AN/AN/AN/A
ALT
ALTIMMUNE INC
$499.10MN/A0.00%N/AN/AN/AN/A
SPRB
SPRUCE BIOSCIENCES INC
$29.05MN/A0.00%N/AN/AN/AN/A
PPBT
PURPLE BIOTECH LTD
$8.61MN/AN/AN/AN/AN/AN/A
ITOS
ITEOS THERAPEUTICS INC
$382.80MN/A0.00%N/AN/AN/AN/A
SRPT
SAREPTA THERAPEUTICS INC
$11.06BN/A0.00%N/AN/AN/AN/A
BGNE
BEIGENE LTD
$13.80BN/A0.00%N/AN/AN/AN/A
SPRY
ARS PHARMACEUTICALS INC
$874.30MN/A0.00%N/AN/AN/AN/A
RVMD
REVOLUTION MEDICINES INC
$6.06BN/A0.00%N/AN/AN/AN/A
PLRX
PLIANT THERAPEUTICS INC
$774.68MN/A0.00%N/AN/AN/AN/A
ZYME
ZYMEWORKS INC
$624.53MN/A0.00%N/AN/AN/AN/A
EYPT
EYEPOINT PHARMACEUTICALS INC
$1.04BN/A0.00%N/AN/AN/AN/A
ARDX
ARDELYX INC
$1.52BN/A0.00%N/AN/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -29.71% over the past year, underperforming other biotech stocks by -4 percentage points.

Incyte has an average 1 year price target of $73.92, an upside of 40.21% from Incyte's current stock price of $52.72.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Incyte, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -12.47% over the past year, overperforming other biotech stocks by 13 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.9% from Harmony Biosciences Holdings's current stock price of $29.19.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -2.27% over the past year, overperforming other biotech stocks by 24 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 164.86% from Voyager Therapeutics's current stock price of $7.74.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 13.98%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 52.87%, which is 39 percentage points higher than the biotech industry average of 13.98%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)


Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.1%, which is -13 percentage points lower than the biotech industry average of 13.98%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.09% in the last day, and down -5.43% over the last week. Dare Bioscience was the among the top losers in the biotechnology industry, dropping -41.65% yesterday.

Dare Bioscience shares are trading lower after Brookline Capital downgraded the stock from Buy to Hold.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -24.48% in the past year. It has overperformed other stocks in the biotech industry by 1 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -2.27% in the past year. It has overperformed other stocks in the biotech industry by 24 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -29.71% in the past year. It has underperformed other stocks in the biotech industry by -4 percentage points.

Are biotech stocks a good buy now?

49.13% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 85.39% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.83x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.